APHA:CA:TSX-Aphria Inc (CAD)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | TSX

Last Closing Price

CAD 6.14

Change

0.00 (0.00)%

Market Cap

CAD 1.77B

Volume

0.92M

Average Target Price

CAD 7.54 (+22.85%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Aphria Inc. cultivates, processes, produces, markets, distributes, and sells medical cannabis in Canada and internationally. The company offers pharmaceutical-grade medical cannabis, adult-use cannabis, and cannabis-derived extracts and derivative cannabis products under the Solei, RIFF, Good Supply, Aphria, P'tite Pof, and Broken Coast brands. It serves patients and consumers through distributors and online. The company is headquartered in Leamington, Canada. Address: 98 Talbot Street West, Leamington, ON, Canada, N8H 1M8

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-20 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BHC:CA Bausch Health Companies Inc

N/A

CAD8.07B N/A 27.89
WEED:CA Canopy Growth Corporation

N/A

CAD8.01B N/A N/A
CRON:CA Cronos Group Inc

N/A

CAD2.44B 2.49 N/A
ACB:CA Aurora Cannabis Inc

N/A

CAD0.97B 1,171.00 N/A
GUD:CA Knight Therapeutics Inc

N/A

CAD0.81B 124.08 12.36
CWEB:CA Charlotte's Web Holdings, Inc

N/A

CAD0.51B 120.37 N/A
HEXO:CA HEXO Corp

N/A

CAD0.49B N/A N/A
HLS:CA HLS Therapeutics Inc

N/A

CAD0.45B N/A 31.71
NEPT:CA Neptune Wellness Solutions Inc

N/A

CAD0.38B 32.20 N/A
OGI:CA OrganiGram Holdings Inc

N/A

CAD0.29B -99,999.99 N/A

ETFs Containing APHA:CA

Symbol Name Weight Mer Price(Change) Market Cap
HMMJ-U:CA Horizons Marijuana Life S.. 0.00 % 0.75 %

N/A

N/A
SEED:CA Evolve Marijuana Fund 0.00 % 0.75 %

N/A

CAD3.63M
HMMJ:CA Horizons Marijuana Life S.. 0.00 % 0.75 %

N/A

CAD0.39B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.44% 86% B 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.44% 86% B 37% F
Trailing 12 Months  
Capital Gain -24.66% 86% B 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -24.66% 86% B 17% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -18.68% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.68% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.78% N/A N/A N/A N/A
Risk Adjusted Return -78.56% N/A N/A N/A N/A
Market Capitalization 1.77B 89% B+ 81% B-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 57.08 33% F 11% F
Price/Book Ratio 0.97 57% F 65% D
Price / Cash Flow Ratio -13.23 82% B- 89% B+
EV/EBITDA 574.40 7% F 0% N/A
Management Effectiveness  
Return on Equity -4.74% 75% C 42% F
Return on Invested Capital -2.80% 71% C- 30% F
Return on Assets 0.07% 82% B- 43% F
Debt to Equity Ratio 22.09% 38% F 74% C
Technical Ratios  
Short Ratio 2.65 50% F 34% F
Short Percent N/A N/A N/A N/A N/A
Beta 2.02 23% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector